Director dealings: Oxford Biodynamics director lowers stake
20th Oct 2023 15:32
(Sharecast News) - Oxford Biodynamics revealed on Friday that Vulpes Testudo Fund had offloaded 777,000 ordinary shares in the AIM-listed biotechnology company.
Read moreOxford BioDynamics secures US billing code for prostate test
3rd Oct 2023 10:41
(Sharecast News) - Precision test developer Oxford BioDynamics has successfully secured a proprietary laboratory analysis (PLA) code from the American Medical Association's (AMA) Current Procedural Terminology (CPT) Editorial Board, it announced on Tuesday.
Read moreOxford Biodynamics first-half losses widen
30th May 2023 07:48
(Sharecast News) - Oxford BioDynamics reported revenue of £0.22m in its first half on Tuesday, up from £0.09m in the same period a year earlier.
Read moreOxford Biodynamics raises £9.1m in placing
7th Oct 2022 12:57
(Sharecast News) - Biotech company Oxford BioDynamics said on Friday that it has conditionally raised around £9.1m in a placing to accelerate the commercialisation of a cancer test.
Read moreOxford BioDynamics awarded $0.91m US PACT grant
31st Aug 2021 12:48
(Sharecast News) - Oxford BioDynamics has been awarded an FNIH Partnership for Accelerating Cancer Therapies (PACT) grant, it announced on Tuesday, to use its 'EpiSwitch' diagnostic platform for the accurate prediction of a patient's response to immune checkpoint inhibitors (ICIs) from a routine blood sample.
Read moreOxford Biodynamics inks agreement with Agilent Technologies for EpiSwitch kit
31st Mar 2021 08:05
(Sharecast News) - Biotechnology company Oxford BioDynamics has signed a supply and resale agreement with US firm Agilent Technologies for the manufacture and sale of its new EpiSwitch Explorer Array Kit.
Read moreOxford BioDynamics names Matthew Wakefield as chairman
14th Dec 2020 09:29
(Sharecast News) - Biotechnology company Oxford BioDynamics appointed a new chairman on Monday.
Read moreOxford BioDynamics losses widen in first half
16th Jun 2020 13:15
(Sharecast News) - Biotechnology company Oxford BioDynamics reported a fall in revenue to £0.2m in its interim results on Tuesday, from £0.6m a year earlier.
Read moreDirector dealings: Oxford Biodynamics interim chairman ups stake
11th Dec 2019 16:11
(Sharecast News) - Oxford Biodynamics revealed on Wednesday that interim chairman Stephen Diggle had purchased 18,309 ordinary shares in the AIM-listed biotechnology firm.
Read moreThree AIM firms celebrate Queen's Award for Enterprise wins
23rd Apr 2019 10:33
(Sharecast News) - Three firms trading on London's AIM market were celebrating wins in the Queen's Award for Enterprise on Tuesday, with Inspiration Healthcare, Ergomed and Oxford BioDynamics all picking up the accolades.
Read moreOxford BioDynamics biomarker to be used in prostate cancer test trial
19th Mar 2019 11:43
(Sharecast News) - Oxford BioDynamics announced on Tuesday that it has signed an agreement with Imperial College London, to utilise its latest 'EpiSwitch' biomarker signature for the blood-based diagnosis of prostate cancer in the 'PROSTAGRAM' trial.
Read moreOxford BioDynamics sets sights on China following GL investment
22nd Aug 2018 08:39
(Sharecast News) - AIM-listed biotechnology company Oxford BioDynamics has launched a strategic partnership with GL Capital, a Chinese healthcare-focused investment group.
Read more